Afficher la notice abrégée

Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma

dc.rights.licenseopenen_US
dc.contributor.authorMEYNARD, Lucie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDINART, Derek
dc.contributor.authorDELAUNAY, Blandine
dc.contributor.authorFLECHON, Aude
dc.contributor.authorSALDANA, Carolina
dc.contributor.authorLEFORT, Felix
dc.contributor.authorGRAVIS, Gwenaelle
dc.contributor.authorTHIERY-VUILLEMIN, Antoine
dc.contributor.authorCANCEL, Mathilde
dc.contributor.authorCOQUAN, Elodie
dc.contributor.authorLADOIRE, Sylvain
dc.contributor.authorMAILLET, Denis
dc.contributor.authorROLLAND, Frederic
dc.contributor.authorBOUGHALEM, Elouen
dc.contributor.authorMARTIN, Sophie
dc.contributor.authorLARAMAS, Mathieu
dc.contributor.authorCROUZET, Laurence
dc.contributor.authorABBAR, Baptiste
dc.contributor.authorFALKOWSKI, Sabrina
dc.contributor.authorPOUESSEL, Damien
dc.contributor.authorROUBAUD, Guilhem
dc.date.accessioned2022-11-02T09:28:55Z
dc.date.available2022-11-02T09:28:55Z
dc.date.issued2022-09-08
dc.identifier.issn1879-0852 (Electronic) 0959-8049 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/170186
dc.description.abstractEnBACKGROUND: Recent studies suggest improvements in response to salvage chemotherapy (CT) after immune checkpoint inhibitors (ICIs) in several types of cancer. Our objective was to assess the efficacy of chemotherapy re-challenge after ICI, compared with second-line chemotherapy without previous ICI in patients with locally advanced or metastatic urothelial carcinoma (la/mUC). METHODS: In this multicentre retrospective study, we included all patients with la/mUC initiating second or third-line chemotherapy from January 2015 to June 2020. We compared patients treated with second-line chemotherapy without previous ICI (CT2) and patients treated with third-line chemotherapy after ICI (CT3). The primary end-point was objective response rate (ORR) in CT3 compared with CT2. Secondary end-points included progression-free survival (PFS) and toxicities. RESULTS: Overall, 553 patients were included. ORRs were 31.0% (95% CI, 26.5 to 35.5) and 29.2% (95% CI, 21.9 to 36.6), respectively, in CT2 and CT3, with no statistically significant differences (P = 0.62). In subgroup analyses, no differences in ORR were observed by Bellmunt risk group, type of chemotherapy (platinum or taxanes), duration of response to first-platinum-based chemotherapy (< or ≥ 12 months) or FGFR-status. Median PFS was 4.6 months (95% CI, 3.9 to 5.1) and 4.9 months (95% CI, 4.1 to 5.5) in CT2 and CT3, respectively, and grade 3-4 hematologic toxicity occurred in 35.0% and 22.4% of patients. CONCLUSION: This large multicentre retrospective study provides clinically relevant real-world data. Chemotherapy re-challenge after ICI in la/mUC achieves ORR and PFS comparable with those obtained in CT2 with an acceptable safety profile. These updated results offer more promising outcomes than historically reported with second-line chemotherapy data.
dc.language.isoENen_US
dc.subject.enUrothelial carcinoma
dc.subject.enImmune checkpoint inhibitor
dc.subject.enChemotherapy
dc.title.enChemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.ejca.2022.08.014en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36088671en_US
bordeaux.journalEuropean Journal of Canceren_US
bordeaux.page43-53en_US
bordeaux.volume175en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03836416
hal.version1
hal.date.transferred2022-11-02T09:29:04Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=European%20Journal%20of%20Cancer&amp;rft.date=2022-09-08&amp;rft.volume=175&amp;rft.spage=43-53&amp;rft.epage=43-53&amp;rft.eissn=1879-0852%20(Electronic)%200959-8049%20(Linking)&amp;rft.issn=1879-0852%20(Electronic)%200959-8049%20(Linking)&amp;rft.au=MEYNARD,%20Lucie&amp;DINART,%20Derek&amp;DELAUNAY,%20Blandine&amp;FLECHON,%20Aude&amp;SALDANA,%20Carolina&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée